Characterization of vaccine antigens of meningococcal serogroup W isolates from Ghana and Burkina Faso from 2003 to 2009 by Ispasanie, Emma et al.
F1000Research
Open Peer Review
, National School ofGeorgina Tzanakaki
Public Health Greece
, Griffith University AustraliaKate L. Seib
Discuss this article
 (0)Comments
2
1
RESEARCH ARTICLE
Characterization of vaccine antigens of meningococcal
serogroup W isolates from Ghana and Burkina Faso from 2003
 to 2009 [v1; ref status: indexed, http://f1000r.es/37h]
Emma Ispasanie ,    Gerd Pluschke , Abraham Hodgson , Ali Sie ,
 Calman MacLennan , Oliver Koeberling1
Novartis Vaccines Institute for Global Health, 53100, Siena, Italy
MRC Centre for Immune Regulation, School of Immunity and Infection, College of Medicine and Dental Sciences, University of Birmingham,
Birmingham, B15 2TT, UK
Molecular Immunology Department, Swiss Tropical and Public Health Institute, Basel, 4002, Switzerland
University of Basel, Basel, 4003, Switzerland
Navrongo Health Research Centre, Navrongo, PO Box 114, Ghana
Centre de Recherche en Santé de Nouna, PO Box 02, Nouna, Burkina Faso
Abstract
 is a major cause of bacterial meningitis and aNeisseria meningitidis
considerable health problem in the 25 countries of the ‘African Meningitis Belt’
that extends from Senegal in West Africa to Ethiopia in the East. Approximately
80% of cases of meningococcal meningitis in Africa have been caused by
strains belonging to capsular serogroup A. After the introduction of a serogroup
A conjugate polysaccharide vaccine, MenAfriVac , that began in December
2010, the incidence of meningitis due to serogroup A has markedly declined in
this region. Currently, serogroup W of  accounts for the majorityN. meningitidis
of cases. Vaccines based on sub-capsular antigens, such as Generalized
Modules for Membrane Antigens (GMMA), are under investigation for use in
Africa. To analyse the antigenic properties of a serogroup W wave of
colonisation and disease, we investigated the molecular diversity of the protein
vaccine antigens PorA, Neisserial Adhesin A (NadA), Neisserial
heparin-binding antigen (NHBA) and factor H binding protein (fHbp) of 31
invasive and carriage serogroup W isolates collected as part of a longitudinal
study from Ghana and Burkina Faso between 2003 and 2009. We found that
the isolates all expressed fHbp variant 2 ID 22 or 23, differing from each other
by only one amino acid, and a single PorA subtype of P1.5,2. Of the isolates,
49% had a functional gene and 100% had the  allele 3, whichnhbA nadA
contained the insertion sequence  in five isolates. Of the W isolatesIS1301
tested, 41% had high fHbp expression when compared with a reference
serogroup B strain, known to be a high expresser of fHbp variant 2. Our results
indicate that in this collection of serogroup W isolates, there is limited antigenic
diversification over time of vaccine candidate outer membrane proteins (OMP),
thus making them promising candidates for inclusion in a protein-based
vaccine against meningococcal meningitis for Africa.
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Introduction
Neisseria meningitidis is a major cause of bacterial meningitis in the 
African Meningitis Belt1. Between 1993 and 2012, nearly 1 million 
suspected cases were reported with 100,000 deaths, and 80% of the 
cases were caused by serogroup A2. Following the introduction of 
the serogroup A polysaccharide conjugate vaccine MenAfriVac™ in 
2010, the incidence of group A disease decreased, but outbreaks 
of meningitis due to other meningococcal serogroups, in particular 
serogroup W, continue to occur1,3. Serogroup W was responsible for 
an epidemic of around 13,000 cases of meningitis in Burkina Faso 
in 20024 and contributed to a total of 639 deaths in 2012 in the same 
country5. Around 40% of infected people who develop sepsis die 
and survivors often suffer from limb loss, cognitive dysfunction, 
brain damage or visual impairment.
An approach towards developing a broadly-protective meningococ-
cal vaccine for Africa is based on the use of subcapsular antigens 
included in GMMA (Generalized Modules for Membrane Anti-
gens). GMMA are outer membrane blebs from bacteria genetically 
engineered to release large quantities of membrane vesicles, which 
are enriched in outer membrane proteins. Other strain modifications 
are included to increase safety and immunogenicity by the up-
regulation of immunogenic antigens6,7. GMMA from genetically-
engineered strains with up-regulated expression of meningococcal 
factor H binding protein (fHbp) have been shown to provide broad 
protection against African meningococcal isolates from different 
serogroups7. Other outer membrane antigens that have been shown 
to induce the production of bactericidal antibodies include PorA, 
Neisserial adhesin A (NadA)8 and Neisserial heparin-binding anti-
gen (NHBA)9.
To help determine the potential coverage of these antigens in a 
GMMA-based vaccine for Africa, we investigated their genetic 
diversity in serogroup W carriage and disease isolates from Burkina 
Faso and Ghana collected between 2003 and 2009. These two 
countries have suffered repeatedly from meningococcal meningitis 
outbreaks4,10. Focusing on isolates collected over a period of years 
from a defined geographic region provides the opportunity to moni-
tor the dynamics, variation and diversity of surface-exposed anti-
gens over time. 
Materials and methods
Neisseria meningitidis isolates
The N. meningitidis isolates investigated in this study were col-
lected in the Kassena-Nankana District (KND) of Ghana and in the 
Nouna Health District (NHD) in the Kossi region of Burkina Faso. 
Case strains were isolated from the cerebrospinal fluid of meningitis 
patients, and carriage strains were isolated from throat swabs col-
lected in the context of longitudinal carriage surveys. Isolation and 
characterization of the strains has previously been described10–13. 
Ethical clearance was obtained from the Ethics Committee of the 
War Memorial Hospital/Navrongo Health Research Centre in Ghana 
and the Ministry of Health and Local Ethics Committee of the Centre 
de Recherche en Santé de Nouna in Burkina Faso. Informed consent 
was obtained from all study participants. The 31 N. meningitidis 
carriage (n=21) and disease isolates (n=10) used in this study are 
described in the Table 1. The isolates were collected from Burkina 
Faso (n=8) and Ghana (n=23) during the period 2003–2009. The 
isolates were stored frozen in 10% skimmed milk at -80°C until 
analysis. The isolates were molecularly characterized with respect 
to fHbp, porA variable regions (VR), nadA and nhbA genes by 
sequencing. A subset of these isolates was also analysed for their 
fHbp expression level.
Recombinant DNA techniques
The selected strains were sub-cultured on GC agar plates (Becton 
Dickinson, Franklin Lakes, NJ, USA) and incubated overnight at 
37°C, 5% CO2. A loop-full of cells was resuspended in 500 μL sterile 
water and boiled for 10 minutes. The samples were pelleted at 
17,900 g for 5 minutes in a microcentrifuge (Eppendorf). Genomic 
DNA was purified using an Invitrogen PureLink Genomic DNA kit 
(Invitrogen, San Diego, California, USA) according to the manu-
facturer’s instructions. The genes encoding fHbp, PorA VRs, NadA 
and NHBA were PCR amplified from all isolates using the primers 
described in Table 2. The final PCR reaction contained: 0.5 mM 
deoxynucleotide triphosphates, 5 U/mL Taq DNA polymerase, 1× 
Thermopol Reaction buffer (all New England BioLabs, Ipswich, 
USA), 1 μM primer solution (Sigma-Aldrich, St. Louis, Missouri, 
USA) and 100 ng of genomic DNA quantified with a NanoDrop 
ND-1000 Spectrophotometer (NanoDrop Technologies, Wilmington, 
USA). The PCR was performed using the Applied Biosystems 
GeneAmp PCR System 9700 (Applied Biosystems, Foster City, 
USA) with maximum ramping speeds using conditions described in 
Table 3. PCR products were separated by gel electrophoresis using 
a 0.8% Tris base, acetic acid and EDTA (TAE) agarose gel (BioRad 
Laboratories, Hercules, USA). PCR products were purified using 
the PureLink PCR Purification Kit (Invitrogen) according to the 
manufacturer’s instructions. The DNA amount was measured using 
the NanoDrop ND-1000 Spectrophotometer.
DNA sequencing
The primers used for porA VR1 sequencing were 210 and 103L 
(Table 2). We designed primers EI and H for sequencing of the 
VR2 region, by aligning the conserved regions upstream and down-
stream of VR2 using the alignment program Clustal W (http://
www.ebi.ac.uk/Tools/msa/clustalw2/). PorA sequences from the 
following strains of different serogroups were used for the align-
ment: MC58 (GenBank accession number AE002098.2), Z2491 
(AL157959.1), 053442 (CP000381.1), FAM18 (AM421808.1), 
M6190 (AEQF01000026.1), M13399 (AEQG01000023.1) and 
alpha 14 (AM889136.1) using Uniprot. The sequences were read at 
the Novartis Vaccines-Cellular Microbiology and Bioinformatics Unit 
Automated DNA Sequencing Facility, Siena, Italy, on an ABI 3730 
DNA Analyzer. Sequences were analyzed using the Simmonics 
program (version 1.6) and Chromas (version 2.01). fHbp ID, porA 
VR and nhbA alleles were identified using the online Neisseria 
Sequence Typing database (http://pubmlst.org/neisseria). nadA 
sample and reference sequences were exported into the MEGA 
software package (version 5)14 and aligned for the construction of 
phylogenetic trees using the maximum likelihood method with the 
general time-reversible model of evolution and correction for partial 
deletion of gaps (GenBank accession numbers: nadA1 FJ619641.1; 
nadA2 GQ302859.1; nadA3 JN166979.1; nadA4 FJ619644.1; 
nadA5 FJ619645.1). All trees were un-rooted.
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Table 1. Characteristics of serogroup W isolates used in this study. Molecular characterization was 
performed on these isolates by PCR amplification and sequencing of fHbp, porA, nadA and nhbA.
Isolate Source Origin Year fHbp 
variant
fHbp 
ID
PorA 
subtype
nadA 
allele nhbA 
Sequence 
type (ST)
1485* carrier Ghana 2003 2 23 P1.5,2 3 S 11
1487 carrier Ghana 2003 2 23 P1.5,2 3 S 11
1489 carrier Ghana 2003 2 23 P1.5,2 3 S 11
1491 carrier Ghana 2003 2 23 P1.5,2 3 S 11
1494* carrier Ghana 2003 2 23 P1.5,2 3 S 11
1625* case Ghana 2003 2 23 P1.5,2 3 Y 11
1626 case Ghana 2003 2 23 P1.5,2 3 S 11
1627* case Ghana 2003 2 23 P1.5,2 3 S 11
1628* case Ghana 2003 2 23 P1.5,2 3 S 11
1629 carrier Ghana 2004 2 23 P1.5,2 3 N 11
1630* carrier Ghana 2004 2 23 P1.5,2 3 S 11
1632 carrier Ghana 2004 2 23 P1.5,2 3 Y 11
1634* carrier Ghana 2004 2 23 P1.5,2 3 Y 11
1636 carrier Ghana 2004 2 23 P1.5,2 3 Y 11
1681* case Ghana 2003 2 23 P1.5,2 3 Y 11
1682* case Ghana 2003 2 23 P1.5,2 3 S 11
1683* case Ghana 2003 2 23 P1.5,2 3 S 11
1846* carrier Ghana 2004 2 23 P1.5,2 3 Y 11
1848 carrier Ghana 2004 2 23 P1.5,2 3 Y 11
1857* carrier Ghana 2004 2 23 P1.5,2 3 Y 11
1888 carrier Ghana 2004 2 23 P1.5,2 3 S 11
1903* case Ghana 2004 2 23 P1.5,2 3 Y 11
1973 carrier Ghana 2004 2 23 P1.5,2 3 Y 11
2039* case Burkina Faso 2008 2 22 P1.5,2 3 Y 11
2252* case Burkina Faso 2008 2 22 P1.5,2 NA S 11
2716 carrier Burkina Faso 2004 2 22 P1.5,2 3 Y 11
2719* carrier Burkina Faso 2004 2 22 P1.5,2 3 Y 11
2841 carrier Burkina Faso 2005 2 22 P1.5,2 NA Y 11
2855 carrier Burkina Faso 2005 2 22 P1.5,2 NA S 11
2882 carrier Burkina Faso 2009 2 22 P1.5,2 NA S 11
2959* carrier Burkina Faso 2009 2 22 P1.5,2 NA Y 11
*Isolate used for fHbp protein expression analysis.
NA: Inactive nadA due to insertion sequence IS1301.
S: nhba gene with stop codon.
Y: Full length nhba gene
N: No gene product obtained by PCR
Table 2. Primers used for PCR amplification and sequencing of the 
genes fHbp, porA, nadA snd nhbA.
Target 
gene
Primer 
designation 5′-3′ nucleotide sequence Reference
fHbp A1 (Fw) 
B2 (Rv)
GACCTGCCTCATTGAT 
CGGTAAATTATCGTGTTCGTACGGC
[17] 
[17]
porA 210 (Fw) 
H (Rv) 
EI (Fw) 
103L (Rv)
ATGCGAAAAAAACTTACCGCCCTC 
CGCATATTTAAAGGCATAG 
CCAGCCAGGCCATTGATCC 
AACGGATACGTCTTGCTC
[27] 
This study 
This study 
[27]
nadA NadAF (Fw) 
NadAR (Rv)
AACACTTTCCATCCAAAG 
TTACCACTCGTAATTGACG
[23] 
[23]
nhbA Fw 
Rv
GGCGTTCAGACGGCATATTTTTACA 
GGTTTATCAACTGATGCGGACTTGA
[20] 
[20]
Fw: forward; Rv: reverse.
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Western blot analysis of fHbp expression in whole cell 
lysates
For 17 isolates labelled with an asterisk in Table 1, Western blot 
analysis of the fHbp expression level in whole cell samples was per-
formed as described by Seib et al.15. The strains were sub-cultured 
on GC agar and incubated overnight at 37°C with 5% CO2. A 7 mL 
aliquot of Mueller-Hinton broth (Becton Dickinson, Franklin Lakes, 
NJ, USA) supplemented with 0.25% glucose (Sigma-Aldrich) was 
inoculated with single colonies to an optical density at 600 nm (OD600) 
of 0.12–0.16. The suspensions were incubated at 37°C with 5% CO2 
to an OD600 of 0.6 corresponding to approximately 1.8×108 cfu/ml 
(exponential growth phase). The cells from 1 mL of culture were 
collected by centrifugation at 17,900 g for 5 min in a microcentri-
fuge (Eppendorf), re-suspended in 100 μL phosphate buffered saline 
(PBS) and heat inactivated in a water bath at 56°C for 1 hour. Protein 
concentrations of the lysates were determined using a Lowry protein 
assay kit (BioRad Laboratories, Hercules, USA) with bovine serum 
albumin (Sigma-Aldrich) as a standard. The fHbp amounts were esti-
mated by SDS-PAGE and Western Blot. To 100 μL heat inactivated 
sample we added 100 μL SDS sample buffer (Invitrogen) and 10 μL 
of each sample was loaded on the gel. Recombinant fHbp (rfHbp) 
v.2 of 500, 250, 125 and 60 ng was used as standard. Positive and 
negative controls were whole cell lysates from N. meningitidis group 
B strain 8047 expressing fHbp v.2 and the isogenic fHbp knock-out 
mutant. Proteins were transferred to a nitrocellulose membrane (Inv-
itrogen) using the iBlot system (Invitrogen). After blocking over-
night in 3% milk powder in PBS (Merck, Whitehouse station, NJ, 
USA) at 4°C, fHbp proteins were detected with 1 μg/mL anti-fHbp 
mouse monoclonal antibody JAR31 (IgG2b) raised against recom-
binant fHbp v.3 ID 28, which shows cross-reactivity against most 
fHbp v.2 peptides16. The secondary antibody used was 1μg/mL of 
a horseradish peroxidase-labelled anti-mouse IgG (Invitrogen). The 
membranes were developed using SuperSignal WestPico Chemilu-
minescent Substrate (ThermoScientific, Waltham, Massachusetts, 
USA) according to manufacturer’s instructions, and the signal was 
detected with Amersham Hyperfilm ECL (GE Healthcare, Little 
Chalfont, UK). The amount of fHbp expressed by each isolate 
compared to the standard rfHbp was determined by densitometric 
analysis for three biological replicates using the ImageQuant 400 gel 
documentation system (GE Healthcare). The expression of fHbp by 
the test isolates was reported as percentages of the amount of fHbp 
expressed by bacterial cells compared to the reference strain, known 
to express relatively high amounts of fHbp v.217.
Results
The serogroup W isolates studied are homogenous with 
respect to fHbp and porA sequence variants
PorA is an immunodominant antigen in N. meningitidis, but mul-
tiple subtypes exist with little cross-protection between meningo-
cocci expressing different PorA subtypes. fHbp can be divided into 
three antigenic variants, each of which is divided into sub-variants. 
Individual sequences are classified by a peptide ID number. Within 
each variant group, cross-protection is observed18. From the typing 
analysis of the fHbp and porA genes, all serogroup W isolates tested 
expressed fHbp variant 2, ID 22 (isolates from Burkina Faso) or 23 
(isolates from Ghana), which differ by one amino acid, and PorA 
subtype P1.5,2 (Figure 1 and Supplemental File). Despite the lim-
ited number of isolates studied, these results suggest that between 
Burkina Faso and Ghana, which share a common border, there has 
been conservation of fHbp and PorA antigens among W isolates 
over a period of seven years.
The serogroup W isolates studied have intermediate or high 
fHbp expression
The level of fHbp protein expression can affect susceptibility of 
meningococci to anti-fHbp antibodies. High expressers of fHbp 
are generally more susceptible to killing than low expressers19. We 
measured fHbp expression in 17 isolates. We selected 4 out of 8 
(50%) strains from Burkina Faso and 13 out 23 (56%) strains from 
Ghana for fHbp expression analysis. These were selected to cover 
isolates from different years including the oldest and newest strains. 
Within this group of strains selected, n=2 (50%) of the strains from 
Burkina Faso and n=7 (53%) of the strains from Ghana were case 
isolates, while the remainder were carriage isolates. We prepared 
whole cell extracts of the serogroup W test strains and the serogroup 
B reference strain and compared fHbp levels with defined amounts 
of a fHbp v.2 protein standard by Western blot and densitometry 
measurement (Dataset 1). Expression level of the reference sero-
group B strain 8047 was set to 100% and levels of expression of 
the serogroup W strains were compared with the reference strain. 
Isolates with means below 33% of the reference strain were classi-
fied as low expressers while isolates with expression above 100% 
were categorized as high expressers. Those with mean fHbp expres-
sion between 33–100% were considered intermediate expressers. 
The expression of fHbp among the W isolates was variable, ranging 
from 50–152%, compared to the reference serogroup B strain 8047, 
with 41% of the isolates expressing equal or higher levels of fHbp 
Table 3. Conditions used for PCR amplification of the genes fHbp, porA, nadA and nhbA.
fHbp porA nadA nhbA
 
PCR profile
94ºC, 4 minutes 
 
35 cycles: 
94ºC, 40 seconds 
58ºC, 40 seconds 
68ºC, 40 seconds 
 
Final extension: 
72°C, 5 minutes
94ºC, 5 minutes 
 
30 cycles: 
94ºC, 1 minute 
55ºC, 1 minute 
72ºC, 30 seconds 
 
Final extension: 
72°C, 5 minutes
94ºC, 5 minutes 
 
30 cycles: 
94ºC, 1 minute 
55ºC, 1 minute 
72ºC, 1 minute 30 seconds 
 
Final extension: 
72°C, 5 minutes
94ºC, 4 minutes 
 
35 cycles: 
94ºC, 1 minute 
55ºC, 1 minute 
72ºC, 1 minute 
 
Final extension: 
72°C, 5 minutes
Reference [17] [27] [23] [20]
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Figure 1. FHbp, PorA, NadA and NHBA typing analysis of meningococcal serogroup W isolates from Ghana and Burkina Faso. The 
fHbp variant group is designated according to the classification proposed by Masignani et al.17. FHbp sequence ID, PorA subtype, nadA 
and nhbA allele were determined by sequence query on http://pubmlst.org/neisseria. Each isolate was typed by PCR amplification of each 
respective gene and sequence analysis using bioinformatics software Simmonics, Mega 5 and Chromas. NadA + IS1301: Strains with NadA 
encoding gene containing insertion sequence IS1301. NHBA-/stop codon: Strains lacking the NHBA encoding gene or having nhbA with 
stop codon.
compared to the reference strain (Figure 2). There was no significant 
difference in fHbp expression between case and carrier isolates studied 
(P=0.74, Mann Whitney U test). This indicates that levels of fHbp 
protein on the bacterial surface can vary among strains collected 
from a relatively small region and expressing the same fHbp ID.
The genomes of most serogroup W isolates studied contain 
nadA 
NadA and NHBA induce the production of bactericidal antibodies 
against N. meningitidis serogroup B strains. Wang et al. found that 
nadA was not present among a small number (n=13) of W isolates 
tested as part of an analysis of 896 serogroup B, C, Y and W iso-
lates from the USA, while nhbA was present in 92% of W isolates20. 
Among the African W strains investigated in this study, the nadA 
allele 3 was present in 26/31 (84%) of isolates (Figure 1). Among 
the remaining five W isolates (1 case, 4 carrier isolate), PCR ampli-
fication across the nadA site gave a 2 kb product instead of the 
expected 1 kb product. Western blotting using whole cell lysate 
and polyclonal mouse anti-NadA allele 3 antibody indicated that 
these isolates did not express NadA (Dataset 1). Sequencing of this 
fragment confirmed the presence of the insertion sequence IS1301. 
This 842-bp mobile genetic element is known to cause a number of 
effects including insertions and deletions that result in silent muta-
tions, knock-out of gene expression or regulation of downstream-
located genes. For example, insertion of IS1301 into the capsular 
siaA gene mediates loss of encapsulation resulting in increased 
adherence and entry of meningococci into epithelial cells21,22. 17 out 
of 21 carrier (81%) and 9 out of 10 (90%) case isolates had a nadA 
gene. Previous reports found that nadA is present in about 50% of 
group B case isolates, but underrepresented in carrier isolates23.
fHbp
variant
74%
26%
22
23
fHbp
ID
PorA
VR
Presence
of NadA
gene
Presence
of NHBA
gene
NadA
full length
NadA +
IS1301
16%
84%
NHBA +
NHBA - /
stop codon
51% 49%
 v.2
n=31
100%
 P1.5,2
100%
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NhbA was present in 30/31 (94%) of the meningococcal isolates 
studied. However, genetic sequencing in these isolates revealed 
a stop codon for 15/30 isolates, which has not previously been 
reported. The alleles of the remaining strains were identified as 
allele 17 (Supplemental File) using the Neisseria typing database 
available at http://pubmlst.org/neisseria/NHBA/.
Dataset 1. Data of fHbp and NadA expression in serogroup W 
isolates from Ghana and Burkina Faso
http://dx.doi.org/10.5256/f1000research.3881.d36326
Quantifications of the amount of fHbp in whole cell extracts from the 
serogroup W strains are shown in the file ‘Quantifications of fHbp.
csv’. The analysis of NadA and fHbp expression in whole cell extracts 
is shown in the figure provided ‘NadA and fHBP expression.tif’. 
Details can be found in the text file provided.
Discussion
Since the introduction of a meningococcal A polysaccharide con-
jugate vaccine MenAfriVac® in the African Meningitis Belt, out-
breaks of meningitis caused by non-serogroup A meningococci, 
particularly W, are occurring with increased frequency. The devel-
opment of a protein-based vaccine that can provide broad protec-
tion is an attractive prospect. An approach to understanding whether 
protein-based vaccines could have an impact on reducing the bur-
den of meningococcal disease in the African Meningitis Belt, is to 
examine the genetic diversity of carriage and disease isolates of 
serogroup W. In this study, we focused on investigating the molecu-
lar diversity of four OMP vaccine antigens of 31 carriage and dis-
ease isolates of serogroup W from Ghana and Burkina Faso. The 
strains studied were isolated between 2003 and 2009 and contain 
conserved fHbp, porA and nadA genes, suggesting little antigenic 
diversification over time. A stop codon was identified among over 
half of the nhbA genes sequenced and was associated with a lack of 
expression of NHBA protein.
Previously, Pajon et al. performed a molecular characterization of 
106 invasive meningococcal isolates from 13 African countries, 26 of 
which were from Burkina Faso and 3 from Ghana. Of the serogroups 
W analysed in the study, 58% were fHbp variant 2, in common with 
all W isolates from our collection, while 34% were variant 1 and 
8% variant 3. Concordant with our findings, 98% of W were PorA 
subtype P1.5,2 or a related subtype indicating a marked homo-
geneity of PorA type among African serogroup W isolates19. A 
more recent longitudinal study found that a hypervirulent ST-11 
serogroup W clone was responsible for most meningococcal dis-
ease in 2011 and 201224. All the isolates expressed PorA 1.5,2 and 
96.4% had FetA (iron-regulated outer-membrane protein which is 
involved in uptake of siderophores25) variant F1-1. In accordance 
with our study, these two previous studies emphasise the limited 
diversification of major OMPs in the serogroup W meningococcal 
population in Africa. Studies with isogenic mutants with differ-
ent expression levels of fHbp suggested that low fHbp expression 
contributes to resistance to anti-fHbp bactericidal activity19. It has 
been suggested that sparse distribution of antigens on the bacte-
rial surface impedes cross-linking of two IgG anti-fHbp antibod-
ies to correctly spaced epitopes26. Consequently, the antibodies 
cannot engage the complement protein C1q, preventing activation 
of the classical complement pathway. In the present study, the 
serogroup W isolates were found to express medium to high lev-
els of fHbp when compared with a serogroup B strain known to 
express naturally relatively high levels of fHbp17, and there was 
no significant difference in expression between case and carrier 
isolates. This, together with the conservation of the fHbp ID among 
Figure 2. Expression of fHbp in meningococcal serogroup W isolates from Ghana and Burkina Faso, assessed by Western blotting. 
Bars represent the mean percentage from three biological replicates compared with the expression of fHbp of the reference group B strain 
8047, a high expresser of fHbp variant 2 ID 77, which was set at 100%. Isolates with means below 33% were classified as low expressers 
while isolates with expression above 100% were categorized as high expressers. Values between 33–100% were considered as intermediate 
expression. Bars represent standard errors.
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carrier and case isolates indicates that both carrier and case isolates 
could be targets of vaccine-induced anti-fHbp antibodies. NadA 
has emerged as an important protein for adhesion and invasion, and 
has been shown to elicit bactericidal antibodies8. In this study, the 
presence of the nadA gene in most case and carrier strains isolated 
from African countries suggests that NadA could be a potentially 
important vaccine antigen to be included in a GMMA vaccine for 
Africa.
Conclusion
This longitudinal study of meningococcal serogroup W isolates 
from two African countries, together with the findings of other stud-
ies, suggests that there is limited antigenic variation of meningo-
coccal outer membrane proteins that induce bactericidal antibodies. 
These findings support a strategy of using protein-based vaccines, 
such as GMMA, to prevent meningococcal meningitis in Africa 
caused by serogroup W.
Data availability
F1000Research: Dataset 1. Data of fHbp and NadA expression 
in serogroup W isolates from Ghana and Burkina Faso, 10.5256/
f1000research.3881.d3632628
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